Updated on Jun 30, 2022 | Cardiology
Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart disease; it causes thickening of the heart muscle without a clinical cause to explain the extent of thickening observed.
HCM causes symptoms of dyspnea or shortness of breath, chest pain, exercise intolerance, syncope or fainting, and uncommonly, sudden cardiac death (SCD). It affects individuals of all ages but most commonly presents after age 30. Many patients with HCM have a relatively benign course and can have normal life expectancy, and symptoms can be managed with first-line pharmacologic agents like beta blockers or verapamil. However, a quarter of patients will experience in their course either severe disabling symptoms or SCD. (more…)
Updated on Jun 30, 2022 | Health Navigator
“Faster care hasn’t cut heart attack deaths in hospitals.”
A USA Today article noted “The Medicare metric for timely heart attack treatment is … “door-to-balloon” time — the time between when a heart attack patient arrives in the ER and when the balloon angiography begins — researchers found that the percentage of heart attack patients who die while in the hospital, about 5%, hasn’t changed.”
“Irreversible damage from a heart attack can begin in 30 minutes. Most tissue death occurs in the first two to three hours…” “A new study suggests that speeding up hospital care isn’t enough to save lives … A better predictor of survival might be ‘symptom to balloon time’…”
(more…)
Updated on Jun 30, 2022 | Cardiology, Inside, Research
In a groundbreaking, multi-centered randomized trial published in The New England Journal of Medicine, researchers, co-led by Mount Sinai’s David H. Adams, MD, determined that a catheter-based heart procedure to replace an aortic valve was superior to surgery for patients who have symptomatic severe aortic stenosis with increased risks. The findings, based on a clinical trial involving 795 patients treated at 45 institutions across the nation, were simultaneously presented by Dr. Adams at the 63rd Annual Scientific Session of the American College of Cardiology on Saturday, March 29, and represent a major advance for heart patients who are at high risk for surgery.
(more…)
Updated on Jun 30, 2022 | Cardiology, Inside, Research
An injectable nanoparticle that delivers HMG-CoA reductase inhibitors, or statins, which directly inhibit atherosclerotic plaque inflammation could represent a new frontier in the treatment of heart disease. This novel approach is being developed by researchers at Icahn School of Medicine at Mount Sinai, who have seen promising results in mice models and plan to translate their findings to humans within the next few years.
(more…)
Updated on Jun 30, 2022 | Inside, Your Health
The Mount Sinai Hospital Cardiac Care Unit (CCU) was awarded a 2014 Beacon Award for Excellence from the American Association of Critical-Care Nurses (AACN), the leading society of acute- and critical-care nurses.
(more…)
Hypertrophic Cardiomyopathy (HCM) is the most common inherited heart disease; it causes thickening of the heart muscle without a clinical cause to explain the extent of thickening observed.
